PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.06%
Positive EBIT growth while TRAW is negative. John Neff might see a substantial edge in operational management.
7.06%
Positive operating income growth while TRAW is negative. John Neff might view this as a competitive edge in operations.
10.36%
Positive net income growth while TRAW is negative. John Neff might see a big relative performance advantage.
28.30%
Positive EPS growth while TRAW is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
28.30%
Positive diluted EPS growth while TRAW is negative. John Neff might view this as a strong relative advantage in controlling dilution.
24.68%
Share count expansion well above TRAW's 9.47%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
24.68%
Diluted share count expanding well above TRAW's 9.47%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
17.79%
Positive OCF growth while TRAW is negative. John Neff would see this as a clear operational advantage vs. the competitor.
17.79%
Positive FCF growth while TRAW is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-19298.96%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-3628.66%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
45.61%
3Y OCF/share CAGR at 50-75% of TRAW's 87.65%. Martin Whitman would suspect weaker recent execution or product competitiveness.
-15204.15%
Negative 10Y net income/share CAGR while TRAW is at 23.95%. Joel Greenblatt sees a major red flag in long-term profit erosion.
97.68%
5Y net income/share CAGR above 1.5x TRAW's 23.95%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
59.13%
3Y net income/share CAGR 50-75% of TRAW's 89.70%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
9892.41%
Equity/share CAGR of 9892.41% while TRAW is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
293.35%
Equity/share CAGR of 293.35% while TRAW is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
201.29%
Positive short-term equity growth while TRAW is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
67.39%
Positive asset growth while TRAW is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
64.49%
Positive BV/share change while TRAW is negative. John Neff sees a clear edge over a competitor losing equity.
No Data
No Data available this quarter, please select a different quarter.
13.21%
R&D growth drastically higher vs. TRAW's 11.42%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
-38.56%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.